Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12979898 | 0.82 | PDE2A (0.43) | ATML3MBTL1TDP1ADRB2ADRB3 | |
| SCHEMBL4630315 | 0.82 | SRC (0.46) | ATML3MBTL1TDP1CYP2D6CYP2C9 | |
| SCHEMBL16682784 | 0.82 | SRC (0.46) | ATML3MBTL1TDP1CYP2D6CYP2C9 | |
| SCHEMBL517908 | 0.82 | ATM (0.44) | ATML3MBTL1POLBSMN1; SMN2CNR2 | |
| SCHEMBL17357501 | 0.81 | L3MBTL1 (0.61) | ATML3MBTL1TDP1CYP2D6PTGS2 | |
| SCHEMBL66018 | 0.81 | L3MBTL1 (0.61) | ATML3MBTL1TDP1CYP2D6PTGS2 | |
| SCHEMBL9966433 | 0.80 | CYP1A2 (0.46) | ATML3MBTL1POLBSMN1; SMN2MMP1 | |
| SCHEMBL8170317 | 0.80 | FFAR2 (0.49) | ATML3MBTL1POLBCYP2D6CYP2C9 | |
| SCHEMBL9838868 | 0.80 | TDP1 (0.38) | TDP1POLBSMN1; SMN2GRM8GRM7 | |
| SCHEMBL2431670 | 0.80 | FFAR2 (0.49) | ATML3MBTL1POLBCYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996563-B1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2012-03-21 | — | — | EP | disclosed |
| US-8129365-B2 | Water-soluble, fluorescent compounds for detection of potassium ions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-06 | — | — | US | disclosed |
| US-8030308-B2 | Bicyclic sulfonamide derivatives which are L-CPT 1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2011-02-24 | — | — | US | disclosed |
| US-7879845-B2 | Liver carnitine-dependent palmitoyltransferase (L-CPT1) inhibitors such as 4-{[4-(5-Chloro-2-methoxy-benzenesulfonyl)-3,4-dihydro-2H-benzo[1,4]thiazine-6-carbonyl]-amino}-benzoic acid, used for the treatment of non-insulin dependent diabetes; antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080311041-A1 | Water-Soluble, Fluorescent Compounds for Detection of Potassium Ions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-18 | — | — | US | disclosed |
| WO-2007044866-A2 | WATER-SOLUBLE, FLUORESCENT COMPOUNDS FOR DETECTION OF POTASSIUM IONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | ATM 1981/4885L3MBTL1 1943/4885TDP1 947/4885 |
| US-20080311041-A1 | Water-Soluble, Fluorescent Compounds for Detection of Potassium Ions | TACR2, KCNJ8, TAC3 | ATM 2312/4885L3MBTL1 2225/4885TDP1 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.